From the Research
Admilparant, an LPA1 antagonist, has been shown to slow lung function decline in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), with a treatment difference of 1.4% and 3.2% in FVC, respectively, compared to placebo 1. The study, published in the American Journal of Respiratory and Critical Care Medicine, demonstrated that admilparant was safe and well-tolerated, with similar frequencies of diarrhea and transient blood pressure reductions compared to placebo 1. Key findings from the study include:
- Rates of change in percentage of predicted FVC over 26 weeks for IPF were -2.7% (placebo), -2.8% (30 mg), and -1.2% (60 mg) and for PPF were -4.3% (placebo), -2.9% (30 mg), and -1.1% (60 mg) 1
- Treatment discontinuations due to adverse events were similar across IPF arms and lower with admilparant (2.5% [30 mg]; 0% [60 mg]) versus placebo (17.1%) for PPF 1 The results of this study support the use of admilparant as a potential treatment option for patients with IPF and PPF, and further evaluation in phase 3 trials is warranted 1.